REVERSED INNOVATION
We find new indications for existing technologies
THE MEANING OF
REVERSED INNOVATION
We find new indications for existing technologies.
Through our research, we work relentlessly to improve lives by addressing unmet medical needs.
Reversed Innovation is our core value. It reflects our commitment to transforming existing products or technologies to solve new, previously overlooked, or underexplored medical challenges.
As a leader in the biopharmaceutical industry, Reversed Innovation aligns with our broader mission: to repurpose proven solutions in novel ways that deliver meaningful impact for patients worldwide.
TRUSTED DEVELOPMENT
Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and participated in securing successful IPOs of 3 companies in the BioPharma Industry:
- OXiGENE Inc. (OTLC)
- Genmab A/S (GMAB)
- Y-mAbs Therapeutics, Inc. (YMAB)
NEWS
Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment
PRESS RELEASE Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025 FOR IMMEDIATE RELEASE - Date: May 5th, 2025 Clinical Study Demonstrates Improved Locoregional Control with Nimorazole in...
Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration
PRESS RELEASE Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX’s induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will...
Interim Financial Report Q4 2024
PRESS RELEASE In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers...
AFYX THERAPEUTICS HQ
Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
Phone: +45 7174 7174
info@afyxtx.com
AFYX NORWAY
Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
Phone: +47 2396 7174